Identification of the susceptible loci associated with T2DM complication risks, such as renal and cardiac comorbidities, may support early identification of T2DM patients with an increased risk, while identification of SGLT2 inhibitors targets may support targeted therapeutic interventions through the analysis of a panel of genetic markers [333]. Here, SLC5A2 is linked to type 2 diabetes mellitus.